Targeted Therapies for Advanced Non-Small Cell Lung Cancer

被引：3
|
作者：
Starakis, Ioannis [1 ]
Nikolakopoulos, Achilleas [2 ]
Mazokopakis, Elias E. [3 ]
机构：
[1] Patras Univ Hosp, Rion 26500, Greece
[2] Patras Univ Hosp, Dept Med, Div Oncol, Rion 26504, Greece
[3] Naval Hosp Crete, Dept Internal Med, Khania, Greece
来源：
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING | 2012年 / 15卷 / 08期
关键词：
Non-small cell lung carcinoma; targeted treatments; PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; CHEMOTHERAPY-NAIVE PATIENTS; COLONY-STIMULATING FACTOR; P53; GENE-TRANSFER; TRANSFERASE INHIBITOR R115777; PREVIOUSLY TREATED PATIENTS; CISPLATIN PLUS GEMCITABINE; IN-SITU HYBRIDIZATION; PROTEIN-KINASE-C;
D O I：
10.2174/138620712802650513
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
The incorporation of targeted agents has considerably improved the management of patients with advanced non-small cell lung cancer (NSCLC) over the last years. The main targets include the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF). Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. Moreover, several other agents targeting critical pathways in lung carcinogenesis are currently under preclinical or clinical evaluation. This review presents an update on the role of targeted agents in advanced NSCLC. In addition, we present the main clinical studies investigating the activity of these agents in NSCLC and we provide recent data with respect to future therapeutic strategies.
引用
收藏
页码：641 / 655
页数：15
相关论文
共 50 条
  • [1] Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
    Kumar, Mukesh
    Ernani, Vinicius
    Owonikoko, Taofeek K.
    [J]. MOLECULAR ASPECTS OF MEDICINE, 2015, 45 : 55 - 66
  • [2] Targeted therapies in advanced non-small cell lung cancer: Success or failure?
    Szutowicz E.
    Konopa K.
    Jassem J.
    [J]. memo - Magazine of European Medical Oncology, 2011, 4 (1) : 23 - 26
  • [3] Targeted therapies for non-small cell lung cancer
    Papaetis, G. S.
    Roussos, C.
    Syrigos, K. N.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (27) : 2810 - 2831
  • [4] Targeted therapies for non-small cell lung cancer
    Dempke, Wolfram C. M.
    Suto, Tamas
    Reck, Martin
    [J]. LUNG CANCER, 2010, 67 (03) : 257 - 274
  • [5] Targeted therapies in non-small cell lung cancer
    Kyle, Fiona
    Spicer, James
    [J]. CANCER IMAGING, 2008, 8 (01): : 199 - 205
  • [6] Targeted therapies for non-small cell lung cancer
    Spicer, J
    Harper, P
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (09) : 1055 - 1062
  • [7] Novel targeted therapies for advanced non-small lung cancer
    Abughanimeh, Omar
    Kaur, Anahat
    El Osta, Badi
    Ganti, Apar Kishor
    [J]. SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 326 - 336
  • [8] Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Moya-Horno, Irene
    Viteri, Santiago
    Karachaliou, Niki
    Rosell, Rafael
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [9] Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients
    C. Gridelli
    P. Maione
    A. Rossi
    C. Ferrara
    G. Colantuoni
    F. Del Gaizo
    D. Nicolella
    C. Guerriero
    [J]. Targeted Oncology, 2006, 1 : 13 - 22
  • [10] Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients
    Gridelli, C.
    Maione, P.
    Rossi, A.
    Ferrara, C.
    Colantuoni, G.
    Del Gaizo, F.
    Nicolella, D.
    Guerriero, C.
    [J]. TARGETED ONCOLOGY, 2006, 1 (01) : 13 - 22
12345